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Abstract: Behçet’s disease (BD) is a polygenic condition with a complex immunopathogenetic background and challenging diagnostic and therapeutic concepts. Advances in genomic medicine have
provided intriguing insights into disease pathogenesis over the last decade, especially into monogenic
mimics of BD. Although a rare condition, paediatric BD should be considered an important differential diagnosis, especially in cases with similar phenotypes. Emerging reports of monogenic mimics
have indicated the importance of genetic testing, particularly for those with early-onset, atypical
features and familial aggregation. Treatment options ought to be evaluated in a multidisciplinary
setting, given the complexity and diverse organ involvement. Owing to the rarity of the condition,
there is a paucity of paediatric trials; thus, international collaboration is warranted to provide consensus recommendations for the management of children and young people. Herein, we summarise
the current knowledge of the clinical presentation, immunopathogenetic associations and disease
mechanisms in patients with paediatric BD and BD-related phenotypes, with particular emphasis on
recently identified monogenic mimics.
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1. Introduction
Behçet’s disease (BD), initially described by Hulusi Behçet, is a multisystem inflammatory vasculitis of unknown aetiology with the clinical triad of aphthous stomatitis,
genital ulceration and uveitis [1]. In the following years, vascular involvement with thrombophlebitis and multisystem features with vital organ involvement were also identified [2,3].
The disease is now characterised by recurrent oral and genital ulceration, inflammatory
eye disease and vascular, cutaneous and neurological involvement. In the International
Chapel Hill Consensus Conference (CHCC) 2012, Behçet vasculitis was reclassified as
a ‘variable’ type, given that it may affect all types and sizes of vessels, although veins
are predominantly involved [4]. Disease onset is usually between the second and fourth
decades of life and is twice as common amongst males, who generally have a more severe
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phenotype. More recently, with the increased awareness of BD in different populations,
paediatric presentation before age 16 has been reported to account for 3.6–26% of cases [5,6].
BD is characterised by exacerbations and remissions; additionally, disease onset is
generally insidious, with the slow accrual of effects on different systems over months
or years, and thus, delayed diagnosis continues to be a major concern [7]. Given the
rarity of the disease, the lack of laboratory diagnostic tests and the high frequency of
non-specific features such as headaches, arthralgia and abdominal pain in children, BD
diagnosis fundamentally depends on clinical judgement [8,9]. Although BD is considered
a single disease entity, clinical features at presentation may broadly vary depending on
gender, geographical area and age of onset [10,11]. The underlying mechanisms of BD
are yet to be fully delineated. Recent discoveries of monogenic mimics of BD such as A20
haploinsufficiency emphasise the prominence of Mendelian genetic factors, especially for
younger patients, but on the whole do not provide clear insights into the pathogenesis of
typical (i.e., non-monogenic) BD [12,13].
In light of the expanding knowledge on BD immunopathogenesis and recent advances
in genomics, herein, we provide a critical analysis of the literature with an emphasis on
aetiopathogenesis, genetic background, BD mimics and clinical evidence for the current
pharmacological treatments available for paediatric BD.
2. Epidemiology
2.1. Incidence and Prevalence
The prevalence of BD in adult patients varies geographically, with increased frequency
in populations living along the Silk Road from Japan to the Eastern Mediterranean basin,
considered to be endemic areas for the condition [14]. Although BD is more common in
Turkey and other parts of the Middle East, increased awareness of the condition in other
countries has resulted in increased recognition outside of these endemic areas [14]. In a
meta-analysis, pooled estimates of prevalence in adult BD patients were 119.8 per 100.000
in Turkey (95% CI: 59.8, 239.9), 31.8 per 100.000 in the Middle East (95% CI: 12.9, 78.4)
and 3.3 in 100.000 in Europe (95% CI 2.1, 5.2) [15]. Ozen et al. demonstrated that the
prevalence of BD in Turkish children is not more than 10 cases per 100.000 [16], whereas
more recently, a prospective epidemiological study conducted in children and young
people with BD younger than 16 years of age in the UK and Ireland showed that the
estimated two-year prevalence was 4.2 per million children (95% CI: 3.2, 5.4) [9]. BD is
reported to occur more rarely in Western European countries, with a prevalence of 0.1 in
100.000 in Sweden, 7.1 per 100.000 in France and 15.9 per 100.000 in Southern Italy [17–19].
In addition to country of residence, ethnicity was shown to be an important factor in
disease prevalence. In a French epidemiological study, BD rates were significantly higher
in immigrants of North African and Asian ancestries living in the Paris area as compared
to those of European origin [11]. Interestingly, disease rates in immigrant populations
were not as high as those among people who lived in their home countries, indicating the
role of environmental factors in disease pathogenesis. Likewise, geographical variation
in disease expression is also suggestive of environmental effects and epigenetics [14]. For
example, gastrointestinal manifestations are more common in Japan but rare in Turkey. In
contrast, vascular involvement is more frequent in Turkey and Middle Eastern countries as
compared to the Far East [14].
2.2. Demographics and Clinical Features
The mean age of onset in paediatric BD significantly varies between different studies,
from 4.87 to 12.3 years [6,20]. Children and young people with BD generally initially
present with fewer symptoms than required to fulfil diagnostic criteria, and therefore, the
time from the first symptom to diagnosis is approximately 3–5 years [6,10,21]. Recent
epidemiological studies tend toward an equal female-to-male sex ratio. Though study
results have been conflicting, it is important to note that significant symptom variability
has been shown between genders in different studies, with increased disease severity in
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males, including more frequent vascular and ocular involvement [10,21,22]. Of note, genital
ulceration was reported to be more common in females in some studies [9,20,23].
3. Aetiopathogenesis
3.1. Aetiology and Immunopathogenesis
The aetiopathogenesis of BD is still unclear; however, both innate and adaptive immune responses, along with environmental factors and genetic predisposition, are considered important [24]. Environmental triggers may include bacterial infections, viral
infections or responses to autoantigens. Streptococcus is commonly isolated from BD
patients, and Streptococcus sanguis, Helicobacter pylori, Mycoplasma and herpes simplex
virus 1 are some of the microbial agents investigated in the BD aetiology [24]. Oral infections, which were proposed to be associated with the disease by Behçet himself, are still
considered to be potential triggers [1]. In addition to microbial agents, autoantigens such
as heat-shock proteins (HSP) have been shown to play a role in the development of the
disease by acting as molecular mimics [24].
There have been attempts to classify BD under autoimmune diseases, seronegative
spondyloarthropathies and, more recently, autoinflammatory diseases (AIDs) [25]. Evidence supporting the classification of BD in the autoimmune disease group stems from the
following observations: major histocompatibility complex class I (MHC-I) identification,
response to immunosuppressive treatments and the presence of antigen-specific T lymphocytes, such as T-helper 17 (Th 17) pathway involvement and IL-17 and IL-21 production
from Th 17 cells [24,26]. Ombrello et al. [27] provided additional insights into the debate
regarding BD classification, with their data showing that MHC class I molecules could
increase the risk of developing BD through the regulation of both innate NK cells and
adaptive cytotoxic T lymphocytes. On the other hand, there are also some limitations of
the classification of BD under the autoimmunity category. Firstly, the absence of classical
autoimmune features such as female predominance, the lack of association with other
autoimmune diseases and the absence of B cell involvement and autoantibody production
are notable [28]. Secondly, the presence of innate immune cells, namely, neutrophils and
NK cells, and proinflammatory cytokines and chemokines secreted upon activation of these
cells may explain unprovoked hyperinflammatory episodes, which would indeed fit well
with an autoinflammatory condition of multifactorial origin [14,28]. Additionally, a small
number of patients with BD were found to be carriers of mutations in MEFV (encoding
the pyrin protein that plays a key role in the inflammasome complex and whose mutations
cause familial Mediterranean fever), and some had variants in genes encoding Toll-like
receptors (TLR-4) of the innate immune system, further directing BD toward an autoinflammatory pathogenesis [29]. Nevertheless, several important factors need to be taken into
consideration before drawing precise conclusions: (a) most AIDs present early in life and
are associated with a monogenic mutation, which is not the case in BD [30]; (b) vasculitis
is not a prominent feature of monogenic AIDs (with some notable exceptions), whereas a
substantial number of BD patients display vascular involvement at presentation or over the
disease course [30]; (c) anti-IL1ß therapies that have been successfully used in AIDs caused
by defects in the inflammasome have not been convincingly effective for BD [14]. Taken
together, given the complexity in aetiopathogenesis and current evidence supporting the
involvement of both innate and adaptive immunity, it is difficult to classify BD as either
exclusively autoimmune or autoinflammatory.
3.2. Genetic Background
BD is a multifactorial polygenic disease. Disease epidemiology and possible explanations for underlying pathogenic mechanisms suggest a substantial genetic influence [31].
Indeed, the peculiar geographical distribution, cluster of symptoms and familial aggregation of the disease in both paediatric and adult populations (including increased sibling
and twin recurrence rates), with frequencies ranging from 10 to 50%, strongly indicate an
association with different genetic factors [31,32].
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Relatively recently, a novel AID with a familial BD-like phenotype was identified
in association with germline loss-of-function mutations in the TNFAIP3 gene, leading to
haploinsufficiency of the A20 protein, which is a regulatory protein in the NF-κB signalling
pathway [13] (Figure 1B). Consequently, mutant A20 proteins could not restrict NF-κB
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activation, resulting in the overstimulation of inflammatory pathways and overproduction of inflammatory cytokines, such as IL-1β, IL-6 and TNF-alpha, thereby causing an
autoinflammatory phenotype in these patients. In a recent study involving 16 patients with
A20 haploinsufficiency, disease onset was mostly early in life (range: first week of life to
29 years of age); in addition, oral, genital and/or gastrointestinal ulceration were hallmark
features, mimicking BD [41].
Further reports of monogenic mimics of BD have continued to emerge over the last
decade. Papadopoulou et al. [33] reported 11 paediatric cases that were referred as suspected BD and ultimately diagnosed with an underlying monogenic disease (the median
age at the disease onset: 0.6 years (range: 0.2–2.3 years); the median age at the first clinical
visit: 4.1 years (IQR: 2.2–4.8 years)). A wide variety of final diagnoses involving A20
haploinsufficiency, MEFV mutations, chronic granulomatous disease and other monogenic
immunodeficiencies were reached in their cohort, leading the authors to conclude that
monogenic mimics should always be considered in the workup of paediatric BD.
Collectively, these studies suggest that early presentation (<5 years of age), strong
family history and/or incomplete or atypical clinical features (even in older patients) of
BD should be considered ‘red flags’, and monogenic AID or primary immunodeficiency
should be screened for early in the workup [13,33].
4. Diagnostic Criteria
The definition of diagnostic criteria for BD has been a challenging task, given the complexity of the condition, geographical differences in symptom expression and the clustering
of symptoms. The most frequently used diagnostic criteria for BD are the ‘International
Studies Group (ISG)’ and revised ‘International Criteria for BD (ICBD)’ criteria [42,43]
(Table 1). Since the performance of these criteria was suboptimal in paediatric practice,
more recently, an international group of paediatricians proposed paediatric BD classification criteria (PED-BD) from their large cohort of paediatric BD patients [23] (Table 1). In
PED-BD, recurrent oral ulceration is not mandatory, although it is one of the criteria, along
with genital ulceration, skin, eye, neurological and vascular involvement. The pathergy
test has been excluded from PED-BD due to its low specificity. The presence of three out
of six criteria is required for a diagnosis of paediatric BD [23]. In general, the literature
often confusingly refers to these criteria as either diagnostic and/or classification, although
diagnostic and classification criteria are not one and the same. Classification criteria are
defined as a set of disease features used to categorise patients into specific, nearly homogeneous groups with similar disease features [44,45]. They are designed to guide clinical trials
and further research of homogeneous patient cohorts to understand disease pathogenesis
and to assess treatment responses; thus, they should not be used for diagnostic purposes
in individual cases [44,45]. On the other hand, diagnostic criteria are a combination of
clinical signs, symptoms and laboratory, imaging or histopathology tests that can be used
to diagnose an individual patient [44]. In BD, several diagnostic and classification criteria
have been proposed, yet there is a paucity of established consensus criteria in the paediatric
population. Acknowledging this gap, PED-BD classification criteria were developed to
identify subgroups of paediatric cases to better understand the clinical course of the disease
and to guide future clinical trials [23]. Notably, the performance of the PED-BD criteria is
still being evaluated in different cohorts, and current evidence suggests that ICBD is the
most sensitive criteria set [38]. A comparison of the most frequently used ISG and ICBD
diagnostic criteria, along with the consensus PED-BD classification criteria, is provided in
Table 1.
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Table 1. Comparison of different international criteria for Behçet’s disease.

International Criteria

ISG

ICBD *
Value/Item

+
Mandatory (at least 3 attacks/year)
Plus at least 2 of
+
or aphthosis (at least once)
+
+
+

+2

Neurological signs

-

+1

Vascular signs

-

+1

Recurrent oral aphthosis

Genital ulceration
Skin lesions
Ocular lesions
Positive pathergy test

+2

+1
+2
+1

PED-BD Criteria **
Value/Item
+1
(at least 3 attacks/year)
+1
(typically with scar)
+1
+1
N/A
+1
(with the exception of isolated headaches)
+1
(venous thrombosis, arterial thrombosis,
arterial aneurysm)

ISG: International Study Group of BD 1990, ICBD: International Criteria for BD 2014 (* BD diagnosis can be made
if total score is ≥ 4), PED-BD: paediatric criteria for BD 2015 (** 3/6 items are required for a diagnosis of paediatric
BD) (+/-): presence or absence of criterion. N/A: not applicable.

5. Clinical Manifestations
The heterogeneity of presenting symptoms is one of the most striking features of BD
and characterised by unpredictable exacerbation and remission episodes [14]. Considerable
variability in clinical expression might be explained by age of onset, geographic location
and ethnicity. Patients from the Far East exhibit more gastrointestinal symptoms as compared to those of Mediterranean origin [46]. Another interesting aspect of BD is the distinct
clustering of symptoms, such as the acne–arthritis–enthesitis phenotype or the vascular
subset, which indicates the complexity of the disease and further suggests the involvement
of more than one immunopathogenetic mechanism [25]. The most common clinical features
in both paediatric and adult cases—and usually in presenting symptoms—are mucocutaneous involvement with oral and genital ulcers and skin manifestations [6,10,20,47,48].
Ocular, neurological and vascular manifestations were reported to be less common among
paediatric cases but more severe when they do occur [49]. Current evidence suggests a time
interval between the first clinical manifestation and the development of other BD features,
which may result in delayed diagnosis, particularly in younger patients [9,50]. In a cohort
of 817 BD patients from France [51], vasculitis with mainly arterial involvement, male sex
and a high number of disease flares were associated with increased risk of mortality.
5.1. Mucocutaneous Involvement
The majority of paediatric patients present with painful recurrent oral ulcers (ROUs),
which may precede disease onset and can appear on the tongue, lips, palate and
cheeks [9,10,52]. They are usually round, discrete lesions with a yellow-grey pseudomembranous base and heal without scarring [8]. The differential diagnosis for isolated ROU
involves a wide range of diseases, potentially including autoimmune diseases, inflammatory bowel disease (IBD), immunodeficiencies and autoinflammatory syndromes [8].
Genital ulcers (GUs) are less common in children than in the adult population, occurring in 55–83% of patients [9,23]. GUs can be extremely painful, and, in contrast to ROUs,
they tend to be deeper and leave a scar. Typical localisations are the scrotum, glans penis,
vulva, vagina and perianal region; hence, the condition needs to be distinguished from
IBD [8].
BD can cause a wide range of skin manifestations that were shown to be very frequent
among paediatric cases, reported in approximately 90% [10]. Cutaneous manifestations
may involve acneiform (papulopustular) lesions, necrotic folliculitis (more common in
males), erythema nodosum (more common in females), purpura and ulcers.
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The pathergy phenomenon, which can be defined as a non-specific cutaneous pustular
reaction and is performed by needle puncture of the dermis, was formerly used to show
skin hypersensitivity within 24–48 h of the injury. Due to significant variability in the
positive test results between study groups and populations (from 14.5% to 80%), it is now
neither regarded as a diagnostic test in adult patients nor used as a criterion for paediatric
BD [3,23,42,47].
5.2. Musculoskeletal Involvement
Musculoskeletal (MSK) involvement can present as oligo- or polyarticular non-erosive
inflammatory arthritis or arthralgia in children [20,23,48]. Although knees and ankles are
reported to be the most frequently affected joints, spondyloarthropathy and enthesopathy
can also be observed, which is consistent with reports suggesting the classification of BD
under seronegative spondyloarthropathies or MHC-I-opathies [14].
Although myositis is rarely associated with BD, both generalised and localised myositis have been reported in paediatric BD [52,53].
5.3. Ocular Involvement
The most common ocular manifestations of BD include anterior and posterior uveitis,
panuveitis, retinal vasculitis and retinitis [8,23,47,54], the prevalence of which varies significantly, from 8.7% in the United Kingdom to 66.2% in an Iranian paediatric cohort [20,48].
Anterior uveitis is reported to be more frequent in patients younger than 10 years old,
while panuveitis tends to occur later in the disease course [23]. Complications may involve
cataracts, maculopathy, posterior synechiae, retinal detachment and optic atrophy [54]. In a
recent prospective paediatric BD cohort, visual loss due to severe uveitis and enucleation
was reported [9]. Male sex was found to be associated with an increased rate and severity
of ophthalmic involvement in BD [10,54].
5.4. Vascular Involvement
BD can affect vessels of any size and type; hence, it is classified as ‘variable’ vasculitis
in the revised Chapel Hill consensus on the nomenclature of vasculitides [4]. Inflammation
of the vessel wall resulting in thrombus formation is usually the main pathologic feature.
In the consensus classification of paediatric BD, vascular involvement (one of the criteria)
refers to venous and arterial thromboses and/or arterial aneurysms [23]. Vascular manifestations were reported in 6.5% to 32% of patients in paediatric cohorts from various
countries [20,23,55,56]. Similar to ocular symptoms, vascular signs were also found to be
more common in males in different studies [23,55,56]. In a retrospective chart review of
21 paediatric cases with at least one episode of thrombosis, cerebral venous sinuses were
most frequently affected (in more than half of patients), followed by lower extremities [57].
In the same study, thrombophilia measurements were unremarkable in the majority of
the cases (14/21), while 4/21 had positive anticardiolipin antibodies, 2/21 had protein C
deficiency and 1/21 had a positive lupus anticoagulant test [57]. In a retrospective study
in Turkey, 11/34 (32%) paediatric BD patients developed vascular involvement during
follow-up [55]. Amongst these 11 patients, 9/11 had only venous involvement, 1/11 had
only arterial involvement and 1/11 had both arterial and venous involvement [55]. In
addition, 6/11 were reported to have neurovascular involvement, while 2/11 developed
pulmonary artery aneurysms [55]. Cohorts from the UK [9,20] and Italy [56] showed less
frequent vascular signs in paediatric BD—mainly with venous thrombosis of the central
nervous system or lower extremities [14]. In an international collaborative study with
86 paediatric BD cases from Turkey, France, Saudi Arabia and Iran, 10 episodes of venous thrombosis in 8 patients were observed; lower extremities, inferior vena cava and
cerebral vessels were the most commonly affected areas [10]. Arterial complications with
thrombosis and aneurysms occurred in six patients, and pulmonary arteries were the most
frequently affected, resulting in haemoptysis [10]. In another study involving 12 paediatric
cases with central venous sinus thrombosis (CVST), headache was universal at presentation
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(100%), followed by vomiting (25%) and blurred vision (16.7%) [58]. The transverse venous
sinus was affected in the majority (75%), followed by the superior sagittal sinus [58]. Of
12 patients, 4 had another venous thrombosis in addition to CVST [58]. Likewise, in a
cohort of 26 paediatric neuro-BD cases, CVST was confirmed in 23/26, the majority of
whom presented with headaches [59].
5.5. Central Nervous System Involvement
Central nervous system (CNS) involvement is reported in 5% to 30.9% of cases in paediatric cohorts [10,20,56,60]. Both parenchymal and non-parenchymal vascular lesions can
lead to CNS manifestations in paediatric and adult BD [59]. In a large cohort with 26 paediatric neuro-BD cases, 3/26 had parenchymal involvement, which was confirmed by clinical
examination and magnetic resonance imaging (MRI) [59]. Although non-specific headaches
are the most common presenting symptom in paediatric neuro-BD, meningoencephalitis,
idiopathic benign hypertension and cranial nerve palsies have also been reported; therefore,
detailed neurological examination is warranted [10,56]. In the aforementioned international
cohort study by Kone-Paut et al. [10], other CNS features were meningitis (9%), benign
intracranial hypertension (4%), hemiparesis or paraparesis with spastic quadriparesis (4%),
seizures (3%) and peripheral neuropathy including sixth nerve palsy. Severe disability
was reported in 8/10 patients with paediatric neuro-BD from the same cohort, attributed
to meningoencephalopathy or other neurologic deficits [10]. Four of the heavily affected
neuro-BD children also developed organic psychiatric disorders, including memory loss
and personality changes for one patient. In a UK cohort of 28 paediatric BD patients [20],
13 neuro-BD cases were identified, of which 11/13 reported frequent (more than once a
week) headaches, 1/13 had seizures and 1/13 developed neurogenic bladder dysfunction
during the disease course [20]. Computed tomography and/or MRI of the brain was
performed in 6 cases; in 2/6 patients, sagittal sinus thrombosis was detected, while 4/6
had normal imaging [20]. In a recent prospective study, sensorineural deafness was also
reported in one patient with paediatric BD [9].
5.6. Gastrointestinal Involvement
Gastrointestinal manifestations wax and wane in paediatric BD. Abdominal pain,
gastritis and diarrhoea have been reported as the most frequent gastrointestinal symptoms in different studies [10,20,23,56]. Ulcerative lesions of the gastrointestinal tract and
perianal region, haematemesis, melaena, hepatomegaly and gastric perforation were also
reported, albeit infrequently [23,55,56]. In a study by Nanthapisal et al. [20], gastrointestinal
tract endoscopy performed in 10 children revealed gastritis (n = 3), colonic ulcers (n = 2),
oesophagitis (n = 1) and oesophageal ulceration (n = 1), while the remaining 3 had no endoscopy findings. Hepatic vein occlusion may lead to Budd–Chiari syndrome, as reported
in one patient in the international cohort studied by Kone-Paut et al. [10].
5.7. Other Uncommon Manifestations
Constitutional symptoms with recurrent unexplained fevers, malaise, fatigue and
mood disorders have been reported [56].
5.7.1. Nephrourological Involvement
Urinary sediment changes with mild proteinuria, haematuria, glomerulonephritis
and tubulointerstitial nephritis have been observed in a small number of paediatric BD
cases [9,10,20,56]. Secondary amyloidosis is extremely rare in children, though documentation exists in adult cohorts [61]. Considering the paucity of data in paediatric cases, further
follow-up studies with international collaboration are needed to identify patients at risk
of developing secondary amyloidosis. Urological manifestations with epididymo-orchitis
and urethritis were also reported in some larger cohorts [10,48].
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5.7.2. Pulmonary and Cardiac Involvement
Pulmonary arterial aneurysms may rarely occur in some paediatric cases and can
present with life-threatening haemoptysis, dyspnoea, cough and chest pain [10,55]. Although very rare in paediatric BD, cardiac involvement with endocarditis, myocarditis,
pericarditis, pericardial effusion and arrhythmias has been reported [10,20].
6. Management and Outcome Measures
Management of BD requires a multidisciplinary team approach due to the heterogeneity of symptoms with diverse organ involvement. The main goal is to suppress inflammatory exacerbations, prevent organ damage and maintain optimal quality of life [14].
Achieving this goal can be challenging because of the lack of standardised outcome measures defining remission [14]. A variety of outcome measures have been used in clinical
trials in the adult population, albeit without validation [62].
Considerable variation in presenting features depending on age, sex, symptom onset
and geography has also led to the development of diverse outcome measures, particularly
in adult BD patients [62]. This has made it difficult to compare study results and optimise
management strategies. In a systematic review evaluating outcome measures used in
adult BD trials, the most commonly used tools for assessing disease activity or severity
were: (1) the Behcet’s Disease Current Activity Form (BDCAF); (2) the Iranian BD Dynamic
Activity Measure (IBDDAM); and (3) Krause’s total severity score for disease severity [62].
In a study assessing the performance of outcome measures in paediatric BD, the Physician
Global Assessment (PGA) score showed a positive correlation with BDCAF and IBDDAM,
indicating the potential use of these measures for future paediatric trials [63]. The lack of
unified and reliable outcome measures for BD in both paediatric and adult populations has
been a major obstacle in designing randomised controlled trials.
EULAR consensus recommendations for adult BD were published in 2018 [64], but
due to the rarity of BD in children, heterogeneity of disease expression and lack of randomised controlled studies in the paediatric population, there are currently no consensus
management guidelines for paediatric BD. Management and treatment strategies have
therefore been based on adult trials and adult cohorts. Topical corticosteroids followed by
colchicine are historically reported as the first-line therapeutic options to control orogenital
ulcerations in the majority of adult and paediatric cases [9,20,21,55,56]. Treatment escalation
and the choice of medication fundamentally depend on organ and system involvement,
but in general, the use of disease-modifying anti-rheumatic drugs (DMARDs), namely,
azathioprine, mycophenolate mofetil, methotrexate or sulphasalazine, have been reported
in different countries [9,55,56]. In refractory cases or cases of severe organ involvement,
anti-TNF and other biologic agents such as anti-interleukin 1 (anakinra or canakinumab),
anti-interleukin 6 receptor (tocilizumab) or interferon-alpha have also been used with
varied success [9,20,55,56]. Of note, no controlled trials have been conducted to show the
efficacy of colchicine or other medications in paediatric BD.
6.1. Management of Orogenital Ulcerations and Skin and Joint Involvement
Topical treatment with corticosteroids and sucralfate can be used for mucocutaneous
lesions, especially if recurrences are infrequent and if they do not impair quality of life. In
patients with frequent recurrences, systemic treatment with short courses of corticosteroids
can be considered, although, in this setting, colchicine would be the first choice of treatment,
considering its safe side-effect profile, low cost and the possibility of avoiding steroid
toxicity [8,12,14,20]. Colchicine has been shown to be more effective in controlling genital
ulcers, arthritis and erythema nodosum as compared to oral lesions [65], but it has been
widely used and suggested as a first-line systemic option in mucocutaneous disease in
EULAR consensus recommendations [64].
The successful use of thalidomide was reported in five children with the improvement
of orogenital ulcers; however, peripheral neuropathy was documented in two patients [66].
The high risk of peripheral neuropathy and teratogenicity has limited thalidomide use [66],
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which has largely fallen out of favour with increased use of anti-TNF. Dapsone has been
another treatment option to control mucocutaneous symptoms in adult BD cases [67],
although haemolytic anaemia is an important adverse side effect of this treatment. Additionally, there is a lack of studies regarding the use of dapsone in paediatric BD.
An oral phosphodiesterase-4 inhibitor, apremilast, has been successfully used in
treating oral and genital ulcerations in the adult population [68].
In colchicine-resistant patients, systemic immunosuppressive therapeutic options
including azathioprine, anti-TNF or apremilast can be considered [8,12]. A randomised
controlled, double-blind trial of azathioprine in the adult population demonstrated that it
was effective in controlling orogenital ulcerations, arthritis and eye disease without causing
serious adverse events [69]. It is important to emphasise that there have been no controlled
trials of azathioprine in paediatric BD patients, although it has been widely and successfully
used for uveitis and vascular and neurological involvement [55,58].
Regarding alternative treatment options, anakinra (IL-1 receptor antagonist) [70] and
ustekinumab (anti-IL-12/23) [71] were used in trials in adult BD patients; orogenital ulcers
showed a partial response to anakinra, and ustekinumab use resulted in the amelioration
of both mucocutaneous lesions and joint symptoms [71].
6.2. Management of Ocular Involvement
Ocular involvement in BD may be sight threatening, and uncontrolled or underdiagnosed uveitis may result in permanent loss of visual acuity and blindness; hence, it should
be recognised and treated promptly in collaboration with an experienced ophthalmologist to achieve early remission [64]. EULAR recommendations suggest that any patient
with BD and inflammatory posterior uveitis should be treated with either azathioprine,
ciclosporin, interferon-alpha or monoclonal anti-TNF-alpha antibodies, and systemic glucocorticosteroids should not be used alone to control eye involvement [64]. Although EULAR
recommendations are based on adult experience, since the evidence is limited to case series
in children, they can be extrapolated to paediatric BD patients. Randomised controlled
trials demonstrated that both azathioprine and ciclosporin are effective in preserving visual
acuity and preventing relapses [69,72]. The successful use of interferon-alpha [73] and
anti-TNF agents such as infliximab [74,75] and adalimumab [76] has been reported in
refractory cases. In terms of anti-TNF choice, a relatively recent comparative study in
177 BD patients with refractory uveitis showed that both infliximab and adalimumab led to
favourable outcomes during a one-year follow-up; however, improvement in ophthalmic
examinations was more remarkable after one year of treatment with adalimumab [77]. Case
reports and retrospective case series in children all reported favourable outcomes in BD
uveitis with anti-TNF use, especially with adalimumab [78,79]. In a retrospective case
report of 34 paediatric BD patients, azathioprine in addition to glucocorticosteroids was
the treatment of choice for 10/12 children with uveitis [55].
An RCT with gevokizumab (IL-1-regulating monoclonal antibody) [80] and secukinumab (anti-IL-17) [81] did not meet their primary end points. Tocilizumab demonstrated
promising outcomes in five adult BD cases with refractory uveitis who previously failed to
respond to IFN-alpha and anti-TNF treatment [82].
Treatment choices should be individualised depending on patient, physician and
health-system-related factors, such as patient age and sex, organ involvement, susceptibility
to infections, tolerability, physician experience and funding for specific medications [14,64],
since there are no trials that demonstrate the superiority of any of the aforementioned
treatments.
6.3. Management of Other Major Organ Involvement and Vascular Disease
Other major organ involvement in BD includes neurological, gastrointestinal and
vascular manifestations.
From a general perspective, EULAR recommendations suggest starting treatment
with high-dose corticosteroids with a slow weaning plan, in addition to the use of non-
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biologic immunosuppressive agents such as azathioprine or ciclosporin for major organ
involvement, and escalation to TNF inhibitors for more severe and refractory cases [64].
There are some exceptions and additional important aspects that need to be considered for
different organ involvement. For instance, ciclosporin should be avoided in neurological
involvement since it was shown to increase the risk of CNS involvement in different adult
case series, possibly via an off-target endothelial toxicity effect [83]. Limited observational
studies with a small number of patients demonstrated the successful use of IL-6 blockade
(tocilizumab) for the neurological involvement of BD. Parenchymal involvement is different
from cerebral venous thrombosis, as the latter is assessed as a vascular manifestation, and
an acute CVST can be treated with a high dose of corticosteroids and a short course of
anticoagulation [84]. In a Turkish retrospective case series of 12 paediatric BD patients
with CVST [58], all patients received intravenous pulse methylprednisolone followed by
slow tapering of oral prednisolone; 11/12 were concomitantly started on azathioprine, and
12/12 received anticoagulation (11/12 with enoxaparin sodium and 1/12 with warfarin
sodium). Only one patient who did not receive azathioprine relapsed at the second year of
follow-up [58].
The management of vascular manifestations involves immunosuppressive agents
and anticoagulation, although controversy remains for the latter, as thrombosis is a consequence of vessel wall inflammation rather than a hypercoagulable state [64]. Treatment
modalities for acute deep vein thromboses include glucocorticosteroids alongside immunosuppressives such as azathioprine, ciclosporin or cyclophosphamide [64]. For refractory
cases, TNF blockade with the consideration of adding an anticoagulant agent was recommended, provided that the bleeding risk is low and pulmonary artery aneurysms are ruled
out [64]. The precise role of immunosuppressive options and anticoagulation is still largely
debated, though study outcomes favour the use of immunosuppressants over anticoagulation for venous thromboses of BD [85]. In the largest cohort of adult BD cases with
296 venous thromboses, multivariate analysis showed that the use of immunosuppressive
treatment and glucocorticosteroids prevented relapses [85]. Further, 3/4 (75%) patients in
the anticoagulant-treated group developed new thromboses whilst on treatment, compared
to 2/16 (12.5%) in the immunosuppressant-treated group. Ahn et al. [86] compared the use
of immunosuppressive therapy alone versus immunosuppressive therapy and anticoagulation, and no significant difference between thrombosis recurrence rates was found between
the two groups.
Although extremely rare in paediatric BD, high dose glucocorticosteroids and cyclophosphamide are recommended for the management of pulmonary artery or cardiac
aneurysms in the updated EULAR consensus, with escalation to TNF inhibitors for refractory cases [64].
For the gastrointestinal manifestations of BD, EULAR recommendations suggest
the exclusion of other possible gastrointestinal pathologies (including ulcers), infections
(including tuberculosis) and inflammatory bowel disease, since gastrointestinal symptoms
can generally be non-specific and abdominal pain is usually the most common presenting
symptom in children [9,64]. Acute exacerbations of gastrointestinal symptoms in BD can be
managed with glucocorticosteroids and disease-modifying anti-rheumatic agents [87]. The
use of 5-ASA and sulphasalazine has been reported to be successful in milder presentations;
however, azathioprine should be the next treatment option for more severe cases, and in
azathioprine non-responsive or refractory cases, escalation to an anti-TNF-alpha agent
and/or thalidomide should be considered [87,88]. Gastrointestinal complications such
as major bleeding, perforation and obstruction may occur; hence, timely recognition and
surgical consultation are crucial in these cases [64].
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7. Mimics of BD
7.1. Monogenic Mimics of Paediatric BD
7.1.1. Haploinsufficiency of A20 (HA20)
Zhou et al. [13] reported on five families of different ethnicities with autosomal dominant, high-penetrance mutations in TNFAIP3 (Table 2), causing a hereditary systemic
autoinflammatory disease via impairment of the regulatory function of the A20 protein.
HA20 patients presented with Behçet-like phenotypes, including oral and genital ulcers,
pathergy, vascular thrombosis and neurological and gastrointestinal involvement (Table 3).
Indeed, whole-exome sequencing in familial BD patients was able to identify loss-offunction mutations in TNFAIP3 [89]. The wild-type A20 protein was shown to suppress the
NF-κB pathway, as opposed to the mutated A20 protein, which resulted in higher NF-κB
signalling activity and thus increased transcription of genes encoding proinflammatory
cytokines such as IL-1β, IL-6 and TNF-alpha. A20 also functions as a negative regulator of
the NLRP3 inflammasome, independent of its role in the NF-κB pathway [13]. This might
explain the activation of caspase-1, the increased production of active IL-1β and IL-18
and hence the autoinflammatory phenotype of the condition. HA20 should be considered
in patients with a family history of BD, early onset of symptoms and recurrent febrile
disease [33,90]. Thus far, HA20 patients with various organ and system involvement have
been reported. For instance, a patient treated for longstanding intestinal BD-like symptoms
was later diagnosed with A20 haploinsufficiency [91].
Table 2. Monogenic mimics of BD with affected gene and protein.
Monogenic Mimics of BD
Disease

Affected Gene

Protein

Role of Protein

Systemic autoinflammatory diseases (SAIDs)
Haploinsufficiency
A20
DADA-2
FMF
Blau syndrome
Otulipenia

TNFAIP3

A20

ADA-2
MEFV
NOD2
OTULIN

ADA-2
Pyrin
NOD2
Otulin

Negative regulation of inflammation via NF-κB pathway
Regulation of cell proliferation and differentiation
Regulation of pyrin–inflammasome complex via caspase-1
Regulation of innate immunity signalling via NF-κB pathway
Regulation of innate immunity signalling via NF-κB pathway

Primary immunodeficiencies (PIDs)
CGD

CYBB, NCF-1,
NCF-2, NCF-4

NEMO

NEMO

NFKB1
RELA (p65)
PFIT

NFKB1
RELA
WDR1

RELA
WD40 repeat protein

N/A
GLA

N/A
Alpha-galactosidase A

Components of
NADPH oxidase
NF-κB essential
modulator

Production of reactive oxygen species in phagocytes
NF-κB signal modulation
Regulation of innate immunity signalling via NF-κB pathway
Regulation of innate immunity signalling via NF-κB pathway
Activation of inflammasome pathway via actin regulation

Others
Trisomy 8
Fabry Disease

Effect on NF-κB pathway
Degradation of glycosphingolipids in lysosomes

ADA-2, adenosine deaminase-2; BD, Behcet’s disease; CGD, chronic granulomatous disease; CYBB, cytochrome
B-245 beta chain; DADA-2, deficiency of adenosine deaminase-2; FMF, familial Mediterranean fever; GLA, αgalactosidase A gene; MEFV, Mediterranean fever; NADPH, nicotinamide adenine dinucleotide phosphate;
N/A: not applicable; NCF, neutrophil cytosolic factor; NEMO, NF-κB essential modulator; NF-κB, nuclear factor
kappa-B; NOD2, nucleotide-binding oligomerization domain containing 2; OTULIN, OTU deubiquitinase with
linear linkage specificity; PFIT, periodic fevers with immunodeficiency and thrombocytopenia; RELA, relative
v-rel reticuloendotheliosis viral oncogene homolog A; TNFAIP3, tumour necrosis factor-alpha-induced protein 3;
WDR1, WD repeat-containing protein 1.
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Table 3. Comparison of clinical manifestations in BD and monogenic mimics.
Organ/System
Involvement
Recurrent oral
aphthosis
Genital ulceration
Ocular
Skin lesions
Pyrexia
Vascular
Neurological
Gastrointestinal
Arthralgia/arthritis
Systemic
inflammation

BD

HA
20

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

√

Immunodeficiency

-

Haematological

-

*
√

Blau
Syndrome

DADA-2

FMF

Otulipenia

-

-

-

-

CGD

NEMO

NF-κB

RELA

PFIT

Trisomy
8

√

√

√

√

√

√

√

√

√

√

√

*
√

√

-

-

-

√

√

√

*
√

√

√

√

√

√

√

√

√

√

√

√

√

√

-

-

-

√

√

√

*
*

√
√

-

√
√

*
√

√

√

√

√

*
√

√

√

√

√

*
-

√
√

-

-

-

-

-

√
*

*
√

√

√
√
√

√

√

√
√
√

*

*
√

*

*

√

√

√

√

√

√

-

-

√

*
√
*
√

Fabry
Disease
√

√
*
√

√
√

√

√

-

-

√

√

Different clinical features observed in BD and monogenic mimics. BD, Behcet’s disease; CGD, chronic granulomatous disease; DADA-2, deficiency of adenosine deaminase-2; FMF, familial Mediterranean fever, HA 20, A20
haploinsufficiency; NEMO, NF-κB essential modulator; NF-κB, nuclear factor kappa-B; PFIT, periodic fevers with
immunodeficiency and thrombocytopenia; RELA, relative v-rel reticuloendotheliosis viral oncogene homolog A.
(*) Clinical feature has not been reported in the literature but may be associated. (-) Clinical feature has not been
reported in the literature and is unlikely to be observed for that diagnosis.

7.1.2. Otulipenia (Loss-of-Function Mutations in OTULIN)
Zhou et al. [92] reported a BD-like autoinflammatory disease phenotype in four
affected patients with neonatal-onset fever, neutrophilic dermatosis/panniculitis and failure
to thrive but without a primary immunodeficiency. Loss-of-function mutations were
detected in OTULIN (FAM105B), a protein playing a role in the regulation of innate immune
signalling complexes, mainly NF-KB. Affected patient fibroblasts and peripheral blood
mononuclear cells (PBMCs) carrying mutated OTULIN showed a substantial defect in
the deubiquitination of the target molecules, causing enhanced activation of the NF-KB
signalling pathway and thus an increase in proinflammatory cytokines that can delineate
the autoinflammatory phenotype [92]. The identification of loss-of-function mutations in
OTULIN has provided further insight into the emerging spectrum of ubiquitin pathwayassociated autoinflammatory conditions, along with A20 haploinsufficiency [92,93].
7.1.3. Deficiency of Adenosine Deaminase-2 (DADA-2)
In 2014, DADA-2 was described as a novel monogenic autoinflammatory condition with
early-onset vasculopathy, lacunar strokes, livedoid rash and other neurovascular manifestations [94]. Following this, the identification of patients and further insight into the condition
revealed a presentation with haematological involvement and immunodeficiency [95]. Subsequently, case series carrying ADA2 mutations and displaying a novel combination of
Behçet-like manifestations were reported [96] (Table 3). In the same report involving three
families, two sisters from the same family were initially diagnosed with BD and had a partial
response to treatment; an ADA2 mutation was subsequently identified using next-generation
sequencing [96]. One sibling presented with genital ulcers, recurrent fever and arthralgia
and developed vertigo and erythema nodosum during the disease course, while the other
sibling presented with recurrent oral aphthae and erythema nodosum [96].
7.1.4. Other Systemic Autoinflammatory Syndromes (SAIDs) and Periodic
Fever Syndromes
Several typical features of BD overlap with those of SAIDs; therefore, these syndromes
should be considered in differential diagnoses [97] (Table 3). For instance, cryopyrinassociated periodic syndrome (CAPS) and mevalonate kinase deficiency/hyperimmunoglobulin D syndrome may both present early in life with oral ulceration and gastrointestinal
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symptoms [97]. Similarly, the presence of the familial Mediterranean fever gene mutation
(MEFV) Met694Val was found to be associated with an increased frequency of BD in the
Turkish population [29]. Uveitis represents another example of overlapping features, as it
can also be seen in CAPS, TRAPS and Blau syndrome.
7.1.5. Primary Immunodeficiencies (PID)
1. Chronic granulomatous disease (CGD)
CGD is a monogenic PID characterised by an impaired oxidative burst reaction that
leads to inadequate neutrophil phagocytosis in response to bacterial and fungal infections [98]. Typical features include abscesses and granulomatous lesions of the skin, lungs,
lymph nodes and liver [99]. Patients can present with mucocutaneous lesions, which
might lead to the consideration of other differential diagnoses. In a recent case report of
a 9-year-old-girl with recurrent oral aphthae and non-specific gastrointestinal symptoms,
unusual infectious complications during the disease course led to genetic analysis revealing
a characteristic mutation for CGD [98]. Papadopoulou et al. also described a case with
a compound heterozygous mutation in NCF-1 that caused CGD in their monogenic BD
mimic cohort [33].
2. PID caused by mutations in the NF-KB signalling pathway
Several monogenic diseases associated with PIDs have recently been discovered and
reported to display BD-like phenotypes [100]. Most of these associated genes, identified
via whole-exome (WES) and whole-genome sequencing studies, were found to have a role
in the NF-KB signalling pathway, which might shed light on associations with BD as one of
the aetiopathogenetic mechanisms [100] (Figure 2). Mutations in TNFAIP3 that impair the
normal functioning of this pathway were previously discussed. In the following section,
we focus on other mutations that play a role in NF-KB dysregulation, some of which are
known to cause NF-KB-related autoinflammatory diseases displaying BD-like features [97].
i. NEMO (NF-κB essential modulator)
X-linked mutations in NEMO are known to be associated with incontinentia pigmenti
(IP) in females and hypomorphic NEMO deficiency syndrome in males. [101]. Heterozygous mutations in NEMO were found to be associated with familial BD [102] and the
concurrence of BD in two different IP cases [103]. Autoinflammatory features in NEMO
deficiency, such as arthritis, colitis and dermatitis, were attributed to the failure of NEMO
to recruit the A20 protein, thereby resulting in the loss of inhibition of the pathway [104].
ii. NF-κB1 (nuclear factor kappa B)
Polymorphisms of NFKB1 were thought to be associated with BD, particularly in ocular
involvement [105]. Yenmis et al. supported this hypothesis by demonstrating an increased
risk of BD in Turkish patients with polymorphisms in this gene [106]. Following this,
Kaustio et al. reported three unrelated Finnish patients who presented with characteristic
features of BD and were eventually found to have heterozygous mutations in NFKB1 that
gave rise to distinct immunological phenotypes [107].
iii. RELA (p65) (relative v-rel reticuloendotheliosis viral oncogene homolog A)
Using WES, Adeeb et al. recently identified five familial cases of a novel RELAtruncating mutation that resulted in BD-like mucocutaneous ulcerations and neuromyelitis
optica in three generations of an Irish family [108]. Data from this case series indicated that
loss-of-function mutations in RELA impaired NF-κB signalling and increased apoptosis,
causing the BD-like phenotype [108] (Figure 1C).
3. Periodic fevers with immunodeficiency and thrombocytopenia (PFIT)
PFIT is a recently described hereditary autoinflammatory syndrome caused by a
mutation in the actin regulatory gene, WDR1 [109]. WDR1 and actin regulation play key
roles in the activation of the inflammasome pathway in autoinflammation [109]. Standing
et al. described two Pakistani girls born to consanguineous parents presenting with severe
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Figure 2. Overview of the canonical NF-κB signalling pathway and the role of A20 and OTULIN
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7.1.6. Trisomy 8
BD has increasingly been recognised in association with constitutional trisomy 8 mosaicism and acquired trisomy 8 secondary to myelodysplastic syndromes in adults [110,111].
Activation of the NF-κB pathway might be the underlying pathology for the BD-like phenotype in these patients [112].
7.1.7. Fabry Disease (Lysosomal Storage Disease)
Fabry disease is an X-linked lysosomal storage disorder associated with mutations
in the GLA gene that result in the deficiency of a lysosomal enzyme, alpha-galactosidase
A, thereby causing abnormal accumulation of glycosphingolipids in lysosomes, which is
responsible for the clinical phenotype [113]. In their recent report, Papadopoulou et al. described one patient who was initially diagnosed with paediatric BD with fever of unknown
origin, recurrent oral ulceration, myalgia, colitis and a skin rash reminiscent of panniculitis [33] (Table 3). Despite treatment with corticosteroids and cyclophosphamide and
maintenance with azathioprine, cerebral venous thromboses occurred, which prompted
genetic testing, and WES revealed a mutation in GLA that confirmed the diagnosis of Fabry
disease [33].
7.1.8. Other Monogenic Mimics of BD
In addition to the abovementioned monogenic mimics of BD, Papadopoulou et al.
reported one more case with a clearly pathogenic variant in the AP1S3 gene, which is classically associated with pustular psoriasis and deranged trafficking of Toll-like receptor 3 [33].
Furthermore, in the same case series, two further cases with likely pathogenic variants
in other genes were described [33]. Mutation in the tyrosine-protein kinase LYN gene
was detected in one case who presented with fever, recurrent mouth ulcers, panniculitis,
testicular and abdominal pain. In the other case, a novel STAT1 gain-of-function variant
was identified, consistent with the diagnosis of chronic mucocutaneous candidiasis [33].
7.2. Non-Monogenic Mimics of BD
The list of differential diagnoses in BD is broad. Viral, fungal and bacterial infections, including tuberculosis, should always be considered, especially with mucocutaneous,
gastrointestinal and ocular involvement. Monogenic autoinflammatory syndromes are
discussed above as important differentials; additionally, non-monogenic periodic fever
syndromes, such as periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis
syndrome (PFAPA), can masquerade as BD in infancy and early childhood [114]. Conversely, patients initially diagnosed with PFAPA may ultimately declare themselves as
having BD later in life, since the immunopathogenesis somewhat overlaps between these
two diseases [115]. Manthiram et al. identified genetic similarities in BD, PFAPA and
recurrent aphthous stomatitis—with stronger HLA associations in more severe cases—and
proposed naming these conditions ‘Behçet’s spectrum disorders’ [115].
Prothrombotic conditions must also be remembered and investigated in those presenting with thromboses. Other non-monogenic mimics of BD are considered below.
7.2.1. Inflammatory Bowel Disease (IBD)
BD significantly overlaps with IBD, as both conditions present with gastrointestinal
symptoms, oromucosal ulcerations, skin manifestations, uveitis and joint involvement [116].
EULAR recommendations suggest excluding possible underlying pathologies, including
IBD, NSAID ulcers and tuberculosis, before attributing symptoms to intestinal BD [64].
Gastrointestinal manifestations of BD were shown to be more common in the Far East,
especially in Japan, but rather infrequent in Eastern Mediterranean [117]. Symptoms of
non-specific abdominal pain and diarrhoea resemble Crohn’s disease, and BD-associated
ulcers generally occur in the terminal ileum [14]. Vascular involvement with Budd–Chiari
syndrome, bleeding and perforation can complicate intestinal BD [14]. Mucosal biopsies
in BD demonstrate chronic or active mucosal inflammation, as well as vasculitic findings,
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which can help distinguish the condition from IBD [14]. Of note, anorectal disease and
granuloma formation are considerably more specific to Crohn’s disease [25]. Genital ulcers
are not seen in IBD, although perineal fistula in Crohn’s disease may be mistaken for
genital ulceration.
7.2.2. Seronegative Spondyloarthropathies (SpA)
As mentioned, BD was initially included in the spondyloarthropathy group because of
joint and gastrointestinal involvement. However, it was then understood that, unlike SpA,
there was no association with HLA-B27 in BD patients; instead, the majority of BD patients
were carriers of HLA-B51, and axial skeletal arthritis was not a prominent feature [14].
Recently, controversy regarding the classification of BD under SpA has arisen for two main
reasons: firstly, there may be a common immunopathological pathway involved in BD,
ankylosing spondylitis (AS) and psoriatic arthritis (PsA), such as IL-10, IL-17 and IL-23;
secondly, the acne–arthritis–enthesopathy cluster of BD is associated with SpA-related
symptoms [14]. As previously discussed, ERAP-1 gene polymorphisms have been found
to be associated with MHC class I and reported as susceptibility loci for AS and PsA.
Subsequently, since BD, AS and PsA are associated with variants in HLA encoding MHC
class I, these conditions are now described by some as ‘MHC-I-opathies’ [14].
7.2.3. Other Vasculitides
Vasculitis in BD may mimic other types of inflammatory vasculitides since it may involve vessels of any size and type [4]. Nevertheless, venous involvement is a unique feature
of BD vasculitis, and there is no necrotizing vasculitis in small vessels as in anti-neutrophil
cytoplasmic antibody-associated vasculitides, nor are there immune complexes [118]. The
pulmonary artery aneurysms seen in BD can also be observed in Takayasu arteritis, although they are of particular prognostic significance in BD since they are associated with
poorer outcomes [97].
Hughes–Stovin syndrome (HSS) is another extremely rare systemic vasculitic disease
that has also been considered a severe variant of BD. The condition is characterised by
widespread deep vein thromboses and pulmonary and/or bronchial artery aneurysms
with high morbidity and mortality rates [119]. In the context of disease severity and a few
paediatric case reports [120,121], HSS should also be considered in the young.
7.2.4. Neutrophilic Dermatoses
Neutrophilic dermatoses are a heterogeneous group of non-infectious systemic diseases characterised by non-neoplastic neutrophilic inflammatory infiltration of the skin and
frequently associated with multisystemic diseases [122]. BD, pyoderma gangrenosum and
acute febrile neutrophilic dermatosis (Sweet’s syndrome) can be included in this group,
and they may all demonstrate a pathergy reaction [122].
8. Comparison of Paediatric and Adult-Onset BD
The expression of symptoms has been shown to differ between children and adult
patients in comparison studies: in general, non-specific gastrointestinal, neurological
symptoms, arthralgia and a positive family history are more pronounced in the paediatric
age group; genital ulceration, ocular symptoms and vascular involvement are more widely
described in adults [6,7,123]. Disease activity scores and severity indexes appear to be
lower in children as compared to adults, although this might be attributed to a shorter
disease course rather than quiescent disease activity [7,8].
9. Conclusions
Emerging evidence on monogenic mimics of BD has emphasised the importance of
early genetic testing, particularly for those with early-onset, atypical features and familial
aggregation, to exclude monogenic diseases masquerading as BD. NGS can also enable
HLA typing, thus effectively providing the opportunity to classify BD as typical (i.e., HLA-
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B51 with no monogenic mutations) or a monogenic BD mimic. Advances in genomics will
presumably lead to the identification of further novel variants that might explain BD-like
presentations and the marked diversity in symptoms. International collaboration is needed
for randomised controlled trials in paediatric BD to scrutinise heterogeneous symptom
expression in different geographical regions and to establish nuanced consensus guidelines
for diagnosis and management in the paediatric population.
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